Availability of data for measuring physician quality performance.

Am J Manag Care

National Committee for Quality Assurance, 1100 13th St NW, Ste 1000, Washington, DC 20005, USA.

Published: January 2009

Objective: To evaluate measurement of physician quality performance, which is increasingly used by health plans as the basis of quality improvement, network design, and financial incentives, despite concerns about data and methodological challenges.

Study Design: Evaluation of health plan administrative claims and enrollment data.

Methods: Using administrative data from 9 health plans, we analyzed results for 27 well-accepted quality measures and evaluated how many quality events (patients eligible for a measure) were available per primary care physician and how different approaches for attributing patients to physicians affect the number of quality events per physician.

Results: Fifty-seven percent of primary care physicians had at least 1 patient who was eligible for at least 1 of the selected quality measures. Most physicians had few quality events for any single measure. As an example, for a measure evaluating appropriate treatment for children with upper respiratory tract infections, physicians on average had 14 quality events when care was attributed to physicians if they saw the patient at least once in the measurement year. The mean number of quality events dropped to 9 when attribution required that the physician provide care in at least 50% of a patient's visits. Few physicians had more than 30 quality events for any given measure.

Conclusions: Available administrative data for a single health plan may provide insufficient information for benchmarking performance for individual physicians. Efforts are needed to develop consensus on assigning measure accountability and to expand information available for each physician, including accessing electronic clinical data, exploring composite measures of performance, and aggregating data across public and private health plans.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693018PMC

Publication Analysis

Top Keywords

quality events
24
health plans
12
quality
11
physician quality
8
quality performance
8
health plan
8
administrative data
8
quality measures
8
primary care
8
number quality
8

Similar Publications

Importance: Rotator cuff tendinopathy represents the most prevalent cause of shoulder pain, the third most common musculoskeletal disorder after low back pain and knee pain.

Objective: The objective of this study was to determine the effectiveness of corticosteroid injection(s), alone or in combination with anesthetic injection or any other physical therapist interventions, compared to physical therapist interventions alone in adults with rotator cuff tendinopathy.

Design: This study was a systematic review and meta-analysis of randomized controlled trials.

View Article and Find Full Text PDF

Chordoma is a rare malignant tumor with a higher incidence in males than in females. There is an increasing number of clinical studies related to tyrosine kinase inhibitors (TKIs), yet the efficacy and safety of different drugs vary. In this single-arm meta-analysis evaluating the efficacy and safety of TKIs for chordoma treatment, 12 studies involving 365 patients were analyzed.

View Article and Find Full Text PDF

Safety profiles of fondaparinux in pregnant women: a systematic review and meta-analysis.

Eur J Clin Pharmacol

January 2025

Department of Obstetrics and Gynaecology, West China Second University Hospital, Sichuan University, No. 20, Renmin South Road, Section 3, Chengdu, 610041, Sichuan Province, China.

Background: The prevalence of conditions necessitating anticoagulation therapy among pregnant women has been steadily increasing. Although low-molecular-weight heparin (LMWH) is commonly used, several studies have investigated the use of fondaparinux in pregnant women. However, the safety profile of fondaparinux in this population remains to be fully elucidated.

View Article and Find Full Text PDF

Background: The efficacy and safety of dupilumab in patients with refractory prurigo nodularis (PN) is well established in clinical trials, but there is a lack of multicenter data regarding its effectiveness and safety in real-world settings.

Methods: Patients with moderate-to-severe PN who initiated dupilumab treatment between July 2023 and January 2024, with a follow-up period of at least 16 weeks at 10 hospitals in China were included. We used peak pruritus numeric rating scale (PP-NRS), investigator global assessment (IGA) for PN, and dermatology life quality index for adults or children (DLQI/CDLQI) to assess disease control status and quality of life impairment, and monitored adverse events to assess the safety.

View Article and Find Full Text PDF

Background And Objective: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the Kirsten rat sarcoma virus (KRAS) G12C mutation. The CodeBreak 200 trial demonstrated that sotorasib, a new drug targeting the G12C-mutated KRAS protein, modestly improved progression-free survival compared with docetaxel in patients whose cancer had progressed after receiving platinum chemotherapy and programmed cell death protein 1 (PD-1) / programmed death ligand 1 (PD-L1) inhibitors as first-line treatment. Consequently, sotorasib received temporary approval in Switzerland.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!